Reoxygenation of hypoxic glioblastoma multiforme cells potentiates the killing effect of an Lnterleukin-13-based cytotoxin

Clinical Cancer Research

Volumn 15, Issue 1, 2009, Pages 160-168

  Liu, Tie Fu ^a,b   Cai, Jiaozhong ^b   Gibo, Denise M ^a   Debinski, Waldemar ^a,b  

^a Brain Tumor Center of Excellence   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIN; DIPHTHERIA TOXIN; FURIN; HYBRID PROTEIN; INTERLEUKIN 13 RECEPTOR; INTERLEUKIN 13 RECEPTOR ALPHA2; OXYGEN; RECOMBINANT DT IL13QM FUSION PROTEIN; RECOMBINANT INTERLEUKIN 13; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL HYPOXIA; CELL KILLING; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG POTENTIATION; ENZYME ACTIVITY; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; REOXYGENATION;

BRAIN NEOPLASMS; CELL HYPOXIA; CELL LINE, TUMOR; CYTOTOXINS; DIPHTHERIA TOXIN; FURIN; GLIOBLASTOMA; HUMANS; IMMUNOTOXINS; INTERLEUKIN-13; INTERLEUKIN-13 RECEPTOR ALPHA2 SUBUNIT; OXYGEN;

EID: 58949090974     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-2151     Document Type: Article

References (45)

1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N EnglJ Med 2005;352:987-96.
2. Brown JM. The hypoxic cell: a target for selective
3. cancer therapy-Eighteenth Bruce F. Cain Memorial Award Lecture. Cancer Res 1999;59:5863-70.
4. Sathornsumetee S, Cao Y, Marcello JE, et al. Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J Clin Oncol 2008;26:271 -8.
5. Thrall DE, Rosner GL, Azuma C, McEntee MC, Raleigh JA. Hypoxia marker labeling in tumor biopsies: quantification of labeling variation and criteria for biopsy sectioning. Radiother Oncol 1997;44:171 -6.
6. Evans SM, Judy KD, Dunphy I, et al. Hypoxia is important in the biology and aggression of human glial brain tumors. Clin Cancer Res 2004;10:8177-84.
7. Irie N, Matsuo T, Nagata I. Protocol of radiotherapy for glioblastoma according to the expression of HIF-1. Brain Tumor Pathol 2004:21:1 -6.
8. Kohshi K, Yamamoto H, Nakahara A, Katoh T, Takagi M. Fractionated stereotactic radiotherapy using gamma unit after hyperbaric oxygenation on recurrent high-grade gliomas. J Neurooncol 2007;82:297 - 303.
9. Ogawa K, Yoshii Y, Inoue O, et al. Phase II trial of radiotherapy after hyperbaric oxygenation with chemotherapy for high-grade gliomas. Br J Cancer 2006;95: 862-8.
10. Chang JE, Khuntia D, Robins HI, Mehta MP. Radiotherapy and radiosensitizers in the treatment of glioblastoma multiforme. Clin Adv Hematol Oncol 2007; 5:894 - 902, 907-15.
11. Debinski W. Local treatment of brain tumors with targeted chimera cytotoxic proteins. Cancer Invest 2002;20:801 -9.
12. Debinski W. Molecular targeting of brain tumors with recombinant cytotoxins. Res Adv Cancer 2007;7: 155-65.
13. Weaver M, Laske DW. Transferrin receptor ligand- targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas J Neurooncol 2003:65:3-14.
14. Kawakami M, Kawakami K; Puri RK. lnterleukin-4- Pseudomonas exotoxin chimeric fusion protein for malignant glioma therapy. J Neurooncol 2003;65: 15-25.
15. Sampson JH, Akabani G, Archer GE, et al. Progress report of a phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-α and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. J Neurooncol 2003:65:27-35.
16. Kunwar S, Prados MD, Chang SM, et al. Direct intracerebral delivery of cintredekin besudotox (IL13- 38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. J Clin Oncol 2007;25:837-44.
17. Kunwar S, Westphal M, Medhorn M, et al. Results from PRECISE: a randomized phase 3 study in patients with first recurrent GBM comparing cintredekin besudotox administered via convection-enhanced delivery with Gliadel wafers. Neuro-oncol 2007;9:531.
18. Debinski W, Obiri Nl, Pastan I, Puri RK. A novel chimeric protein composed of interleukin 13 and Pseudomonas exotoxin is highly cytotoxic to human carcinoma cells expressing receptors for interleukin 13 and interleukin 4. J Biol Chem1995;270:16775 - 80.
19. Debinski W, Gibo DM. Molecular expression analysis of a restrictive receptor for interleukin 13, a brain tumor-associated cancer/testis antigen. Mol Med 2000;6:440-9.
20. Debinski W, Obiri Nl, Powers SK, Pastan I, Puri RK. Human glioma cells overexpress receptors for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and Pseudomonas exotoxin. Clin Cancer Res 1995;1:1253-8.
21. Debinski W, Miner R, Leland P, Obiri Nl, Puri RK. Receptor for interleukin (IL) 13 does not interact with IL4 but receptor for IL4 interacts with IL13 on human glioma cells. J Biol Chem1996;271:22428 - 33.
22. Thompson JP, Debinski W. Mutants of interleukin 13 with altered reactivity toward interleukin 13 receptors. J Biol Chem 1999;274:29944-50.
23. Madhankumar AB, Mintz A, Debinski W. Alanine- scanning mutagenesis of α-helix D segment of interleukin-13 reveals new functionally important residues of the cytokine. J Biol Chem 2002;277:43194-205.
24. LiuTF, Cai J, Gibo D, Debinski W. Variant IL13-directed diphtheria toxin fusion recombinant cytotoxin for the treatment of malignant gliomas. Neuro-oncol 2006;8:429.
25. Iglewski BH, and Kabat D. NAD-dependent inhibition of protein synthesis by Pseudomonas aeruginosa toxin. Proc Natl Acad Sci U S A 1975;72:2284-8.
26. Moehring JM, Inocencio NM, Robertson BJ, Moehring TJ. Expression of mouse furin in a Chinese hamster cell resistant to Pseudomonas exotoxin A and viruses complements the genetic lesion. J Biol Chem 1993;268:2590-4.
27. Inocencio NM, Moehring JM, MoehringTJ. Furin activates Pseudomonas exotoxin A by specific cleavage in vivo and in vitro. J Biol Chem 1994;269: 31831-5.
28. Chiron MF, Fryling CM, FitzGerald D. Furin-mediated cleavage of Pseudomonas exotoxin-derived chimeric toxins. J Biol Chem 1997;272:31707-11.
29. Ogata M, Chaudhary VK, Pastan I, FitzGerald DJ. Processing of Pseudomonas exotoxin by a cellular protease results in the generation of a 37,000-Da toxin fragment that is translocated to the cytosol. J Biol Chem 1990;265:20678-85.
30. Tellier E, Nègre-Salvayre A, Bocquet B, et al. Role for furin in tumor necrosis factor a-induced activation of the matrix metalloproteinase/ sphingolipid mitogenic pathway. Mol Cell Biol 2007;27:2997-3007.
31. Hosaka M, Nagahama M, Kim WS, et al. Arg-X-Lys/ Arg-Arg motif as a signal for precursor cleavage catalyzed by furin within the constitutive secretory pathway. J Biol Chem 1991;266:12127-30.
32. Mercapide J, Lopez De Cicco R, Bassi DE, Castresana JS, Thomas G, Klein-Szanto AJ. Inhibition of furinmediated processing results in suppression of astrocytoma cell growth and invasiveness. Clin Cancer Res 2002;8:1740 - 6.
33. Bassi DE, Lopez De Cicco R, Mahloogi H, Zucker S. Thomas G, Klein-Szanto AJ. Furin inhibition results in absent or decreased invasiveness and tumorigenicity of human cancer cells. Proc Natl Acad Sci U S A 2001;98:10326-31.
34. Leduc R, Molloy SS,Thome BA, Thomas G. Activation of human furin precursor processing endoprotease occurs by an intramolecular autoproteolytic cleavage. J Biol Chem 1992;267:14304-8
35. Hu HY, Huynh PD, Murphy JR, vanderSpek JC The effects of helix breaking mutations in the diphtheria toxin transmembrane domain helix layers of the fusion toxin DAB389IL-2. Protein Eng1998;11:811 -7.
36. Semenza GL. HIF-1: mediator of physiological and pathophysiological responses to hypoxia J Appl Physiol 2000;88:1474-80.
37. Huang LE, Arany Z, Livingston DM, Bunn HF. Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its a subunit. J Biol Chem 1996;271:32253 - 9.
38. Kallio PJ, Pongratz I, Gradin K, McGuire J, Poellinger L. Activation of hypoxia-inducible factor 1α: posttranscriptional regulation and conformational change by recruitment of the Arnt transcription factor. Proc Natl Acad Sci U S A 1997;94:5667 - 72.
39. Liu TF, Cohen KA, Ramage JG, Willingham MC, Thorbum AM, Frankel AE. A diphtheria toxin-epidermal growth factor fusion protein is cytotoxic to human glioblastoma multiforme cells Cancer Res 2003;63: 1834-7.
40. Mintz A, Gibo DM, Slagle-Webb B, Chnstensen ND, Debinski W. IL-13Rα2 is a glioma-restricted receptor for interleukin-13. Neoplasia 2002;4:388-99.
41. Winkler F, Kozin SV, Tong RT, et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloprotetnases Cancer Cell 2004;6:553-63.
42. Batchelor TT, Sorensen AG, di Tomaso E, et al AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007; 11:83-95.
43. Zagzag D, Zhong H, Scalzitti JM, Laughner E, Simons JW, Semenza GL. Expression of hypoxia- inducible factor 1 in brain tumors: association with an- giogenesis, invasion and progression Cancer 2000: 88:2606-18.
44. Zagzag D, LukyanovY, Lan L, et al. Hypoxia-inducible factor 1 and VEGF upregulate CXCR4 in glioblastoma: implications for angiogenesis and glioma cell invasion. Lab Invest 2006;86:1221 -32.
45. Candolfi M, Curtin JF, Nichols WS, etal. Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression. J Neurooncol 2007;85:133 48.